Emergent Biosolutions (NYSE:EBS – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Analyst Ratings
This is a summary of current ratings and price targets for Emergent Biosolutions and Viridian Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Emergent Biosolutions | 2 | 1 | 3 | 0 | 2.17 |
| Viridian Therapeutics | 1 | 0 | 12 | 0 | 2.85 |
Emergent Biosolutions currently has a consensus target price of $10.00, indicating a potential upside of 44.20%. Viridian Therapeutics has a consensus target price of $38.69, indicating a potential upside of 93.46%. Given Viridian Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Emergent Biosolutions.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Emergent Biosolutions | $742.90 million | 0.48 | $52.60 million | ($3.55) | -1.95 |
| Viridian Therapeutics | $70.85 million | 31.98 | -$342.60 million | ($3.37) | -5.93 |
Emergent Biosolutions has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Emergent Biosolutions and Viridian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Emergent Biosolutions | -22.95% | 16.35% | 6.17% |
| Viridian Therapeutics | -505.86% | -72.97% | -42.80% |
Risk and Volatility
Emergent Biosolutions has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.
Institutional & Insider Ownership
78.4% of Emergent Biosolutions shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Emergent Biosolutions beats Viridian Therapeutics on 9 of the 14 factors compared between the two stocks.
About Emergent Biosolutions
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.
